Info

FirstString is a biotechnology company focused on the development and commercialization of therapeutics for scar prevention and tissue regeneration. There is a significant unmet medical need for the prevention of scarring resulting from surgeries and injuries. FirstString is endeavoring to meet that need by developing a class of compounds which form the platform of this exciting technology. FirstString's proprietary therapies modulate intercellular communication to significantly reduce the development of scar tissue and, at the same time, improve the body's ability to produce healthy, functional cells. The lead compound's target is well expressed and has shown efficacy in many tissue types including the skin, spinal cord and internal organs. FirstString's first commercial product will be a topical gel for the prevention of scarring. Based on the consistent and positive early results, FirstString has already received regulatory approval in Europe to enter clinical phase testing.